1. Home
  2. ADPT vs TFSL Comparison

ADPT vs TFSL Comparison

Compare ADPT & TFSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$25.90

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Logo TFS Financial Corporation

TFSL

TFS Financial Corporation

HOLD

Current Price

$16.22

Market Cap

4.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
TFSL
Founded
2009
1938
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.8B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
ADPT
TFSL
Price
$25.90
$16.22
Analyst Decision
Strong Buy
Hold
Analyst Count
9
2
Target Price
★ $28.31
$18.25
AVG Volume (30 Days)
★ 2.3M
601.6K
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
★ 7.88%
EPS Growth
★ 63.89
14.29
EPS
N/A
★ 0.27
Revenue
★ $276,976,000.00
N/A
Revenue This Year
$5.94
$8.17
Revenue Next Year
$22.42
$7.60
P/E Ratio
★ N/A
$59.70
Revenue Growth
★ 54.77
N/A
52 Week Low
$12.00
$12.54
52 Week High
$30.74
$19.49

Technical Indicators

Market Signals
Indicator
ADPT
TFSL
Relative Strength Index (RSI) 44.89 37.80
Support Level $23.73 $16.11
Resistance Level $26.51 $17.00
Average True Range (ATR) 1.43 0.30
MACD -0.37 -0.01
Stochastic Oscillator 12.46 28.90

Price Performance

Historical Comparison
ADPT
TFSL

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About TFSL TFS Financial Corporation

TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.

Share on Social Networks: